The Impact Of Eli Lilly On A Therapy For Mild Alzheimer 's Dementia

The FDA recently has allowed two treatments to be used for Alzheimer patients. One of the treatments is a Partial Glutamate Antagonist, which is an important transmitter to the brain. It is said that Glutamate helps patients more than sugar pills do, however; it is said that too much

Lawrence, J., (2015) Potential dementia treatment target identified using stem cell research. The Pharmaceutical Journal. 2/1/2015. Retrieved 13/5/2015 from

Alzheimer’s disease is a prominent brain disease that effects a massive amount of individuals in the United States. Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, accounting for 60-80% of dementia cases, with no chance of being cured, prevented or decelerating over time (Alzheimer’s Association, 2014). AD is the most well-known form of dementia, causing complications in brain function in the areas of memory, thinking, and behavior (Alzheimer’s Association, 2014). In an effort to gain a deeper understanding of Alzheimer’s disease, researchers create new knowledge about the disease, which is then distributed to the public. The goal in this information disbursement is to find new and inventive ways to treat AD, prevent AD from progressing at such a rapid pace, and aid in the quality of life in those diagnosed with AD as well as caregivers and medical professionals providing treatment to individuals’ with AD.

Alzheimer’s disease is a complex illness that affects the brain tissue directly and undergoes gradual memory and behavioral changes which makes it difficult to diagnose. It is known to be the most common form of dementia and is irreversible. Over four million older Americans have Alzheimer’s, and that number is expected to triple in the next twenty years as more people live into their eighties and nineties. (Johnson, 1989). There is still no cure for Alzheimer’s but throughout the past few years a lot of progress has been made.

Alzheimer’s disease is a brain disease with many different stages that slows one’s lifestyle and has no real cure. Alzheimer’s disease is named after Dr. Alois Alzheimer. The disease first appears around the age of sixty. Studies have concluded that as many as 5.1 million Americans have Alzheimer’s disease. A person with Alzheimer’s loses connections between neurons in the brain (1).

Luckily, there are biotechnology companies trying to solve the growing problems that Alzheimer’s disease is presenting to the public. Despite repeated failures in clinical trials, leading pharmaceutical companies continue to invest time and capital in finding Alzheimer’s disease treatments. 99 percent of therapies in the past decade have come up short. Scientists are bitterly divided on the issue of targeting amyloid to effect the progression of

Alzheimer’s disease is a progressive decline in cognitive function. It affects the brain by damaging brain cells resulting in a decreased in cognitive function, physical mobility, swallowing and fine motor skills. This disease approximately 5.1 million Americans aged sixty-five or older (Alzheimer 's Association, 2015) of which approximately 700,000 will likely die this year (Alzheimer 's Association, 2015) of related symptoms such as aspiration pneumonia due to decreased swallowing ability. The progression of this disease is consistent and cannot be cured or slowed (Alzheimer 's Association, 2015). According to the Alzheimer’s Association, Alzheimer’s is one of the most expensive chronic disease in the United States estimating a cost of 226 billion dollars per year (Alzheimer 's Association, 2015). This debilitating disease is the sixth leading cause of death in the United States (Alzheimer 's Association, 2015).

The utilization of biomarkers for Alzheimer 's malady is as yet viewed as trial and is fitting just for use by specialists as of now. The rules call for approving and institutionalizing the utilization of biomarkers before they can be connected in a clinical setting, similar to a specialist 's office. Biomarkers for Alzheimer 's malady did not exist when the first criteria were produced in 1984, and have been considered seriously as of late. (Garrett, M. D., and Valle, R. (2016).

Over the last 15 years, many promising clinical studies for Alzheimer’s have failed because many of the participants that were tested did not have Alzheimer’s, but another form of dementia. Because of that, in order for someone to be admitted into current drug trials, he/she must test positive for Alzheimer’s biomarkers. Another reason some clinical studies were inconclusive were because of the fact that the disease was so advanced in some patients that it had already caused brain damage (Nierenberg,

Current pharmacological treatment options available to Alzheimer's patients provide only modest and short-acting benefits in exchange for

Alzheimer’s disease is a progressive degenerative brain disease characterized by progressive memory loss, cognitive impairment, and changes in behaviors and personality which has no cure. It is the most common cause of dementia in older adults and is increasing in prevalence in the younger population (Gosar & Bottomley, 2013). Research has shown that there are more than 5 million people in the United States and over 35 million people in the world who suffer from the disease. The number of Alzheimer’s patients increases steadily as the baby boomers age. Researches predicted that the population with Alzheimer’s disease will be doubled by 2030 (Alzheimer’s Association, 2015; Alzheimer’s Disease International, 2013; Black et al., 2010; Mohamed,

Thank you for sharing your thoughts with us. Alzheimer’s disease (AD) is a progressive cognitive disease mostly affect the aging people, but it is not cause because of age. “A common misperception is that AD is a normal or expected occurrence of aging, and that it is part of the typical trajectory of age-related cognitive decline” ( Burock, & Naqvi, 2014, p. 36). The medications these people are taking on daily basis are to stop the progression of the disease instead of improve cognitive function. This is an irreversible. Whatever part of the brain that is already affected will not come back to the previous state. Alzheimer's drugs don't work for everyone, and they can't cure the disease. Over time, their effects wear off. Regine,

Current medications for dementia are limited and there is a need to explore traditional medicinal system to investigate the agents that can prevent progression of memory loss or improve the existing capacity of learning and memory. Thus present study was carried out to evaluate the effects of Ayurveda drug formulations, Tinospora cordifolia (Tc) & Phyllanthus emblica (Pe) with and without Ocimum sanctum (Os) on learning performance and memory of mice. We also tried to investigate the possible mechanisms of these plant drugs for their effects on learning and memory using Scopolamine, Diazepam and Cyclosporine as amnesic agents.

This film highlights the importance of distinguishing among the various dementias that can occur with aging. Mild cognitive impairment (MCI) is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal age-related changes. If you have mild cognitive impairment, you may be aware that your memory or mental function has "slipped." Your family and close friends also may notice a change. But generally these changes aren't severe enough to interfere with your day-to-day life and usual activities. some people with mild cognitive impairment never get worse, and a few eventually get better. According to a mayo clinic studies show that approximately 15% of individuals aged 70-90 have mild cognitive impairment. They really try to remember something but they really can’t. You lose your train of thought when in a conversation it happens over the time of aging. Most of these patients have sleeping problems, memory loss. This mild cognitive impairment goes into Alzheimer’s. They came to the conclusion that they can treat these people with medication which would help a little but the medication doesn’t kill the disease it doesn’t stop the production. But scientist is testing new ways of treating Alzheimer’s which they

Alzheimer's Disease is a condition that affects 50% of the population over the age of eighty five, which equals four million Americans each year. It is becoming an important and high-profile issue in today's society for everyone. There are rapid advancements being made in the fight against this disease now more than ever, and the purpose of this essay is to educate the public on the background as well as the new discoveries. There are many new drugs that are being tested and studied every day which slow down, and may even halt the progress of the disease.